| Date Filed | Type | Description |
| 02/17/2015 |
SC 13G/A
| Flynn James E reports a 0% stake in Optimer Pharmaceuticals, Inc. |
| 11/04/2013 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 10/30/2013 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 10/24/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 10/24/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 10/24/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 10/24/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 10/24/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 10/24/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 10/24/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 10/24/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 10/24/2013 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
| 10/24/2013 |
8-K
| Quarterly results |
| 10/24/2013 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| 10/23/2013 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 10/15/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/10/2013 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 5% stake in OPTIMER PHARMACEUTICALS |
| 10/10/2013 |
SC 13G/A
| FMR LLC reports a 5.4% stake in OPTIMER PHARMACEUTICALS INC |
| 09/18/2013 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 09/18/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 09/18/2013 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 09/13/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 09/13/2013 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 09/10/2013 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 09/06/2013 |
CT ORDER
| Form CT ORDER - Confidential treatment order |
| 08/22/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 08/07/2013 |
10-Q
| Quarterly Report for the period ended June 30, 2013 |
| 08/02/2013 |
8-K
| Quarterly results |
| 08/02/2013 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 08/01/2013 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 08/01/2013 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 08/01/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 08/01/2013 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Agreement and Plan of Merger, by and among Optimer Pharmaceuticals, Inc., Cubist Pharmaceuticals, Inc. and PDRS Corporation",
"Form of Contingent Value Rights Agreement between Cubist Pharmaceuticals, Inc. and Trustee",
"Amendment 1 to Co-Promotion Agreement, between Optimer Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc" |
|
| 07/30/2013 |
425
| Form 425 - Prospectuses and communications, business combinations |
|